Media Coverage

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

NuFFooDS Spectrum, July 31, 2018


A clinical study conducted in India and published in the peer reviewed journal Food & Nutrition Research reported that adults with irritable bowel syndrome (IBS) showed improvement from co-existing depression when they took a probiotic strain Bacillus coagulans MTCC 5856 (2 billion spores per day); subjects of the study given a placebo did not report the same improvement.

This study, Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double blind, placebo controlled, multi-centre, pilot clinical study, published in Food & Nutrition Research, provides evidence of clinical efficacy of B. coagulans MTCC 5856 in patients experiencing major depression symptoms with IBS and supports the hypothesis that the modification of microbial ecology in human gut by supplementing probiotics may be an alternative strategy to ameliorate or prevent depression. The study demonstrates that consumption of probiotic B. coagulans MTCC 5856 may improve gut symptoms and psychological issues i.e. major depression, sleeplessness, and dementia in IBS. This provides new opportunity not only to help patients suffering from gastrointestinal related disorders but also the patients suffering from extra-intestinal disorders such as major depression, quality of sleep and dementia....


Read More...

 

    VISIT US

  • Sabinsa Canada
    1200 Aerowood Drive, Unit 32
    Mississauga, ON L4W 2S7
    Canada

  • +1 905-232-1242
  • +1 437-988-1663
  • info.canada@sabinsa.com

CERTIFICATES

Certificate Logos
Certificate Logos
Certificate Logos
Certificate Logos
Certificate Logos
Certificate Logos

CONTACT US